Topic:

Partnering

Latest Headlines

Latest Headlines

Takeda recruits GE to help discover new liver treatments

The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.

Foundering Aveo strikes a small deal to resurrect its thrice-failed drug

With former collaborator Astellas Pharma long since out the door, Aveo Oncology has found another partner willing to take a shot on the troubled tivozanib, signing a modest deal with Ophthotech to see how the cancer drug fares in eye diseases.

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.

FDA taps Icon to help patients better weigh in on trials

Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.

UPDATED: Merck partners with Bind on a pair of new cancer drug programs

Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.

Astellas sinks deeper roots into Cambridge's hot R&D field with $1.2B pact

Just weeks ago Astellas teamed up with Harvard's Constance Cepko on a new program for a degenerative eye disease. Today it inked a deal with Proteostasis Therapeutics that could be worth up to $1.2 billion while getting Dana-Farber investigators to help hunt down new cancer drugs that can inhibit K-Ras.

UPDATED: AstraZeneca, University of Manchester create new center for advanced drug delivery

The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the  AstraZeneca,  in the latest example of the growing research collaboration between Big  Pharma  and academia.

Takeda drops a $750M schizophrenia drug pact with Intra-Cellular

More than three years after inking a $750 million pact to develop Intra-Cellular's PDE1 inhibitors for cognitive impairment caused by schizophrenia, Takeda is out.

Stratasys, Worrell partner for faster, cheaper 3-D printed medical devices

Making medical device prototypes using 3-D injection molding, rather than traditional aluminum molds, could reduce the costs and time associated with the product creation and iteration process. That's what major 3-D printer Stratasys is betting on with its new partnership with Worrell.

AliveCor heart monitor, app added to GreatCall's health-focused smartphone

GreatCall, maker of mobile health and safety apps, is adding the AliveCor Heart Monitor for detecting atrial fibrillation to its offerings. Alivecor's electrocardiogram can now be mounted to back of the GreatCall3 smartphone and used with the AliveECG app.